Farletuzumab (Morphotek) now in Phase III trial for Ovarian Cancer - 01-Apr-2012

Morphotek/Eisai has completed enrollment of the FAR-131 clinical trial. The study is a pivotal Phase III randomized trial of Farletuzumab in first-relapsed patients with platinum-sensitive ovarian cancer. Farletuzumab is a humanized monoclonal antibody that targets folate receptor alpha (FRA), which is expressed on the majority of non-mucinous epithelial ovarian cancers as well as a subset of other carcinomas.

Related News

Phase II study of AZD6244 (AstraZeneca) shows benefits for patients with Ovarian Cancer

Phase III trial of MORAb 003 (Morphotek/Eisai) for Ovarian Cancer fails to meet primary endpoint

NICE does not recommend Avastin (Roche) as a treatment for Ovarian Cancer

CHMP recommends Avastin with chemotherapy and gemcitabine for Ovarian Cancer

Positive data from Phase III AURELIA trial of Avastin (Genentech/Roche) for Ovarian Cancer patients

Farletuzumab (Morphotek) now in Phase III trial for Ovarian Cancer

Olaparib (AstraZeneca)will not proceed to Phase III in Ovarian Cancer

Phase III study of Tomtovok (Boehringer) meets endpoint for NSCLC

Related Oncology Information

View all

Oncology Clinical Guidelines

Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care

NICE

Prostate cancer: diagnosis and treatment

NICE
View all

Oncology Clinical Trials

Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer

Clinicaltrials.gov 08 April 2013

Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy (CONKO-007)

Clinicaltrials.gov 04 April 2013
View all

Oncology Medical Journal Abstracts

Bone mass density, fracture history, self-reported osteoporosis as proxy variables for estrogen and the risk of non-small-cell lung cancer—A population based cohort study, the HUNT study: Are proxy variables friends or faults?

Lung Cancer 24 April 2013

Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis

Lung Cancer 22 April 2013
View all

Oncology Medical Apps

CCO Oncology inPractice

Free

Cancer Signs and Symptoms

Free

Related Oncology Drugs

Back to top
View all

Latest News

Takeda acquires vaccine maker Inviragen

10 May 2015

Takeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced that Takeda, its wholly owned subsidiary Takeda America...

Read full article

SAR 302503 (Sanofi) successs in JAKARTA study of Myelofibrosis

18 May 2013

Sanofi has announced that the pivotal study, JAKARTA, examining the selective JAK2 inhibitor SAR 302503 for Myelofibrosis versus placebo...

Read full article

Phase III study of NEPA (Helsinn and Eisai) meets endpoint in patients with Nausea

18 May 2013

Top-line results from a pivotal Phase III clinical study investigating NEPA (netupitant and palonosetron), from Helsinn and Eisai, for...

Read full article